69839-83-4

Basic information

• Product Name: dido
• Synonyms: N,3,4-trihydroxybenzamide;Didox, NSC-324360;dido;3,4-dihydroxybenzohydroxamic acid;Didox
• CAS NO: 69839-83-4
• Molecular Formula: C₇H₇NO₄
• Molecular Weight: 169.13
• Mol File: 69839-83-4.mol

Chemical Properties

• Melting Point: 207 °C
• Appearance: /
• Density: 1.571g/cm³
• Refractive Index: 1.677
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.16±0.20(Predicted)
• CAS DataBase Reference: dido(CAS DataBase Reference)
• NIST Chemistry Reference: dido(69839-83-4)
• EPA Substance Registry System: dido(69839-83-4)

Safety Data

• Hazardous Substances Data: 69839-83-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
Didox is used as an antioxidant for reducing oxidative injury markers in the brains of HIV patients with dementia. Its antioxidant properties help mitigate the effects of oxidative stress associated with the condition.
Used in Cancer Treatment:
Didox is used as a radiosensitizer to increase the sensitivity of cancer cells to radiation therapy. By inhibiting ribonucleotide reductase, it contributes to the reduction of bcl-2 mediated resistance to apoptosis, thereby improving the effectiveness of cancer treatment.

InChI:InChI=1/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)

Upstream product

• 932380-55-7 N-(benzyloxy)-3,4-dihydroxybenzamide 

Relevant articles and documents

Inhibitors of the FEZ-1 metallo-β-lactamase

Metallo-β-lactamases (MBLs) catalyze the hydrolysis of β-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a Ki of 6.1 ± 0.7 μM against the FEZ-1 MBL but does not significantly inhibit the IMP-1, BcII, CphA or L1 MBLs.

Protective solutions for organs

Described is a protective solution for avoiding ischemic, storage or ischemia/reperfusion to organs, or to isolated cell systems, or to tissue components after perfusion, surgery, transplantation, or cryopreservation and subsequent reperfusion, which contains alkali ions, and if need be also alkaline earth ions as the electrolyte, a buffer e.g. on a histidine derivation basis, as well as a polyol and/or a saccharide, has an osmolarity of about 290 mosm/l to about 350 mosm/l, as well as a pH value of about 6.8 to about 7.4, and to which hydroxamic acid, and/or one or more hydroxamic acid derivatives are added.

Method of treating hemoglobinopathies

A therapeutic process for treating anemias in primates, including man, particularly those anemias of genetic origin including sickle-cell anemia, which comprises administering to an anemic primate an amount of a polyhydroxy benzoic, mandelic or phenylacetic acid derivative as specified at a dose level sufficient to increase fetal hemoglobin.

Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors

Di, tri and tetrahydroxybenzohydroxamic acids, amides and the corresponding di, tri and tetrahydroxy substituted phenylalkanohydroxamic acids, amides and phenyl esters, ribonucleotide reductase inhibitors.

Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors

Di and trihydroxybenzohydroxamic acids, amides, alkyl substituted amides and phenyl esters, ribonucleotide reductase inhibitors.

HYDROXY BENZOHYDROXAMIC ACIDS AND BENZAMIDES

Di or trihydroxybenzohydroxamic acids or N-substituted benzamides, inhibitors or ribonucleotide reductase

Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: Inhibition of ribonucleotide reductase and antitumor activity

Benzohydroxamic acids inhibit mammalian ribonucleotide reductase and exhibit antineoplastic activity in L1210 leukemic mice. Five new hydroxy- and amino-substituted benzohydroxamic acids (3,4- and 3,5-OH,3,4-NH2, 2,3,4-, and 3,4,5-OH) were prepared and tested along with 12 previously reported benzohydroxamic acids (BHA) for enzyme inhibition and antitumor activity. The most potent enzyme inhibitor in this series was 2,3,4-OH-BHA (ID50=3.5 μM), which is 140 times more potent than hydroxyurea, but its toxicity limited the antitumor activity to a 30% increase in life span of L1210 bearing mice at 125 (mg/kg) day ip for 8 days. The most effective antitumor agent in this series was 3,4-OH-BHA which prolonged the life span of L1210 bearing mice 103% at 600 (mg/kg)/day ip for 8 days.